Search results for "Life Sciences & Biomedicine"

showing 10 items of 253 documents

DNA Methylation and Non-Coding RNAs during Tissue-Injury Associated Pain.

2022

While about half of the population experience persistent pain associated with tissue damages during their lifetime, current symptom-based approaches often fail to reduce such pain to a satisfactory level. To provide better patient care, mechanism-based analgesic approaches must be developed, which necessitates a comprehensive understanding of the nociceptive mechanism leading to tissue injury-associated persistent pain. Epigenetic events leading the altered transcription in the nervous system are pivotal in the maintenance of pain in tissue injury. However, the mechanisms through which those events contribute to the persistence of pain are not fully understood. This review provides a summar…

INFLAMMATORY PAINRNA UntranslatedChemistry MultidisciplinaryAdaptation BiologicalReviewUP-REGULATIONEpigenesis GeneticCpG islandsTranscripció genèticalncRNANeurociènciesnociceptionBiology (General)SpectroscopyGENE-EXPRESSIONGeneral MedicineComputer Science ApplicationsChemistryPhysical SciencesDisease SusceptibilityChronic PainLife Sciences & BiomedicineepigeneticALLEVIATES NEUROPATHIC PAINBiochemistry & Molecular Biologydorsal root ganglionQH301-705.50699 Other Biological SciencesCatalysisCONTRIBUTESInorganic ChemistryDiagnosis DifferentialCENTRAL SENSITIZATION0399 Other Chemical SciencesHumansPhysical and Theoretical ChemistryQD1-999Molecular Biologyspinal dorsal hornmiRNACHRONIC CONSTRICTION INJURYneuropathic pain0604 GeneticsScience & TechnologyChemical PhysicsNERVE INJURYMICRORNAGene Expression ProfilingOrganic ChemistryDNA MethylationCPG-BINDING PROTEIN-2gene transcriptionGene Expression RegulationsiRNARNAWounds and InjuriesBiomarkersInternational journal of molecular sciences
researchProduct

Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeS", a multinational observational cohort study and ESICM Trials…

2019

Pardo-Oviedo, Juan Mauricio/0000-0003-0084-3449; Lopez-Delgado, Juan Carlos/0000-0003-3324-1129; Corradi, Francesco/0000-0002-5588-2608; De Backer, Daniel/0000-0001-9841-5762; POTA, VINCENZO/0000-0001-9999-3388; Tomescu, Dana/0000-0001-9673-5754; Sabetian, Golnar/0000-0001-8764-2150; Girardis, Massimo/0000-0002-2453-0829; Brazzi, Luca/0000-0001-7059-0622; Leone, Marc/0000-0002-3097-758X; Zabolotskikh, Igor Borisovich/0000-0002-3623-2546; De Lange, Dylan/0000-0002-0191-7270; ALMEKHLAFI, GHALEB A./0000-0002-0323-7025; Elke, Gunnar/0000-0002-4948-1605; Grigoras, Ioana/0000-0001-9412-9574; Czuczwar, Miroslaw/0000-0002-9025-6717; Nora, David/0000-0002-1133-7368; Masjedi, Mansoor/0000-0001-6175-9…

Infection riskMaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Antibiotic resistanceTracte gastrointestinal - MalaltiesDefinitionsCritical Care and Intensive Care MedicineTHERAPYDEFINITIONS:Infections::Intraabdominal Infections [DISEASES]0302 clinical medicineIntensive care; Intra-abdominal infection; Mortality; Multidrug resistance; Peritonitis; Sepsis;[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesObservational studySeptic shockIntensive care; Intra-abdominal infection; Mortality; Multidrug resistance; Peritonitis; SepsisComputingMilieux_MISCELLANEOUSCritical Illness/epidemiology[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.Intraabdominal Infections/epidemiologyAbdominal infectionMulticenter study3. Good healthManagementClinical trialCohort[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCohort analysisCommunity acquired infectionCohort studyHumanmedicine.medical_specialtyCarbapenem resistanceCritical IllnessPeritoneal dialysisPeritonitisVancomycin resistant enterococcusMajor clinical studyPeritonitisArticle03 medical and health sciencesAntibiotic resistance[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIntensive careSepsisSettore MED/41 - ANESTESIOLOGIAHumansCritical care medicineHospital infectionAgedScience & TechnologyLiver failureAntibiotic therapymedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyEpidemiologic Studies030228 respiratory systemIntensive Care Unit; Sepsis (Diptera); Septic ShockRisk factorHuman medicineGeneral & internal medicineCongestive heart failureOriginalMultidrug resistanceCohort StudiesRisk FactorsCause of DeathEpidemiologyPrevalenceMedicine and Health SciencesAbdominal abscessSepsis/epidemiologyMiddle agedAntifungal therapy2. Zero hungerPeritonitiAntibiotic agentBiliary tract infectionIntensive care ; Intra-abdominal infection ; Mortality ; Multidrug resistance ; Peritonitis ; SepsisMiddle Aged:infecciones bacterianas y micosis::infección::infecciones intraabdominales [ENFERMEDADES]PREVALENCE:Infections::Sepsis [DISEASES]:técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Methicillin resistant staphylococcus aureusRaonament basat en casosFemaleCritically ill patientLife Sciences & BiomedicineAntifungal agentAdult:Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Predictive value:infecciones bacterianas y micosis::infección::sepsis [ENFERMEDADES]NOSepsisIntra-abdominal infectionCritical Care MedicineInternal medicineGeneral & Internal MedicinemedicineMANAGEMENTJournal Article[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologySepticèmiaMortalitybusiness.industrySeptic shockPancreas diseaseMalnutrition030208 emergency & critical care medicineTyphlitisToxic megacolonIntensive careIntraabdominal InfectionsTherapyLate onset disorderbusiness
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Pliocene colonization of the Mediterranean by Great White Shark inferred from fossil records, historical jaws, phylogeographic and divergence time an…

2020

Aim: Determine the evolutionary origin of the heretofore poorly characterized contemporary Great White Shark (GWS; Carcharodon carcharias) of the Mediterranean Sea, using phylogenetic and dispersal vicariance analyses to trace back its global palaeo-migration pattern. Location: Mediterranean Sea. Taxon: Carcharodon carcharias. Methods: We have built the largest mitochondrial DNA control region (CR) sequence dataset for the Mediterranean GWS from referenced historical jaws spanning the 19th and 20th centuries. Mediterranean and global GWS CR sequences were analysed for genetic diversity, phylogenetic relationships and divergence time. A Bayes factor approach was used to assess two scenarios …

LARGE PREDATORY SHARKSATLANTICMediterranean climateGreat White Shark Mediterranean historical DNA divergence time phylogeography Carcharodon carchariasMIGRATIONEnvironmental Sciences & Ecologydivergence timeMediterraneanphylogeographyLAMNIDAECarcharodon carcharias; divergence time; Great White Shark; historical DNA; Mediterranean; phylogeographyDivergencePaleontologyDISPERSALbiology.animalGreat White SharkCARCHARODON-CARCHARIASColonizationEcology Evolution Behavior and SystematicsScience & TechnologyCarcharodon carchariasEcologybiologyGeography PhysicalPhylogeographyGreat white sharkEXTINCTIONGeographyPhysical GeographyPhysical SciencesCLOSUREPATTERNSGENETIC DIVERSITYLife Sciences & Biomedicinehistorical DNAJournal of Biogeography
researchProduct

eNOS S-nitrosylates β-actin on Cys374 and regulates PKC-θ at the immune synapse by impairing actin binding to profilin-1.

2017

The actin cytoskeleton coordinates the organization of signaling microclusters at the immune synapse (IS); however, the mechanisms involved remain poorly understood. We show here that nitric oxide (NO) generated by endothelial nitric oxide synthase (eNOS) controls the coalescence of protein kinase C-¿ (PKC-¿) at the central supramolecular activation cluster (c-SMAC) of the IS. eNOS translocated with the Golgi to the IS and partially colocalized with F-actin around the c-SMAC. This resulted in reduced actin polymerization and centripetal retrograde flow of ß-actin and PKC-¿ from the lamellipodium-like distal (d)-SMAC, promoting PKC-¿ activation. Furthermore, eNOS-derived NO S-nitrosylated ß-…

Life Sciences & Biomedicine - Other Topics0301 basic medicinePOLARIZATIONIMMUNOLOGICAL SYNAPSEImmunological SynapsesT-LymphocytesPROTEINGolgi ApparatusCYTOSKELETONRetrograde FlowBiochemistryARP2/3 COMPLEXT-CELL-ACTIVATIONProfilinsWhite Blood CellsContractile ProteinsFluorescence MicroscopyAnimal CellsMedicine and Health SciencesPseudopodiaBiology (General)Post-Translational ModificationCells CulturedProtein Kinase CMicroscopyT CellsGeneral NeuroscienceLight MicroscopyNeurochemistryRecombinant Proteins3. Good healthIsoenzymesPOLYMERIZATIONProtein TransportCell ProcessesRNA InterferenceCellular TypesNeurochemicalsGeneral Agricultural and Biological SciencesLife Sciences & BiomedicineResearch ArticleBiochemistry & Molecular BiologyNitric Oxide Synthase Type IIIQH301-705.5Imaging TechniquesRecombinant Fusion ProteinsImmune CellsImmunologyLibrary scienceAntigen-Presenting Cellsmacromolecular substancesBiologyNitric OxideResearch and Analysis MethodsGeneral Biochemistry Genetics and Molecular BiologyCell Line03 medical and health sciencesFluorescence ImagingHumansCysteineNITRIC-OXIDE SYNTHASEBiologyScience & TechnologyBlood CellsRECEPTORGeneral Immunology and MicrobiologyBiology and Life SciencesProteinsCell BiologyActinsS-NitrosylationEnzyme ActivationLuminescent ProteinsCytoskeletal Proteins030104 developmental biologyAmino Acid SubstitutionRETROGRADE FLOWProtein Kinase C-thetaMutationProtein Processing Post-TranslationalNeuroscienceActin PolymerizationPLoS biology
researchProduct

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.

2021

[BACKGROUND & AIMS] Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intra-hepatic bile ducts eventually leads to cirrhosis. Many patients have inadequate response to licensed medications, motivating the search for novel therapies. Previous genome-wide association studies (GWAS) and meta-analyses (GWMA) of PBC have identified numerous risk loci for this condition, providing insight into its aetiology. We undertook the largest GWMA of PBC to date, aiming to identify additional risk loci and prioritise candidate genes for in silico drug efficacy screening. [METHODS] We combined new and existing genotype data for 10, 516 cases and 20, 77…

Liver CirrhosisALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC0301 basic medicineCandidate geneALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC; Genome-Wide Association Study; Humans; Liver Cirrhosis BiliaryItalian PBC Study GroupLD SCORE REGRESSIONJapan-PBC-GWAS ConsortiumGenome-wide association studyLocus (genetics)DiseaseSUSCEPTIBILITYPBCChronic liver diseaseBioinformaticsGENETIC ASSOCIATION1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineUK-PBC ConsortiumGenotypeHumansMedicineNetwork-based in silico drug efficacy screeningGenetic associationScience & TechnologyGastroenterology & HepatologyHepatologyLiver Cirrhosis Biliarybusiness.industryBiliaryChinese PBC Consortium1103 Clinical SciencesALSPACmedicine.diseasePBC Consortia030104 developmental biologyMeta-analysisERN RARE LIVER030211 gastroenterology & hepatologyGenomic co-localizationUK-PBCUS PBC ConsortiumERN RARE-LIVERCanadian PBC ConsortiumbusinessLife Sciences & BiomedicineGenome-Wide Association StudyHuman
researchProduct

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for th…

2020

Background: Across low-income and middle-income countries (LMICs), one in ten deaths in children younger than 5 years is attributable to diarrhoea. The substantial between-country variation in both diarrhoea incidence and mortality is attributable to interventions that protect children, prevent infection, and treat disease. Identifying subnational regions with the highest burden and mapping associated risk factors can aid in reducing preventable childhood diarrhoea. Methods: We used Bayesian model-based geostatistics and a geolocated dataset comprising 15 072 746 children younger than 5 years from 466 surveys in 94 LMICs, in combination with findings of the Global Burden of Diseases, Injuri…

Low income countriesmedicine.medical_treatment030204 cardiovascular system & hematologyGlobal HealthTHERAPYGlobal Burden of Disease0302 clinical medicinePrevalenceGlobal healthMedicineWATER030212 general & internal medicineChildren11 Medical and Health SciencesIncidenceMortality rateIncidence (epidemiology)1. No povertyGeneral Medicine3142 Public health care science environmental and occupational healthDiarrhoea3. Good healthChild PreschoolMiddle income countriesA990 Medicine and Dentistry not elsewhere classifiedTERRITORIESLife Sciences & BiomedicineInfantsDiarrheaAFRICAmedicine.medical_specialtyChildhood deathsRJsanitationDeveloping countryChildhood diarrhoeal morbidityITC-HYBRID03 medical and health sciencesMedicine General & InternalGeneral & Internal MedicineEnvironmental healthSYSTEMATIC ANALYSISLife ScienceHumansHealthcare DisparitiesOral rehydration therapyRisk factorhand washingDeveloping CountriesDisease burdenGlobal NutritionWereldvoedingScience & TechnologySEX-SPECIFIC MORTALITYbusiness.industryCHOLERAPublic healthBayes Theoremdiarrheal diseaseLocal Burden of Disease Diarrhoea CollaboratorsITC-ISI-JOURNAL-ARTICLENAHuman medicineDiarreabusiness
researchProduct

Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

2020

AbstractThere are large between- and within-country variations in COVID-19 death rates. Some very low death rate settings such as Eastern Asia, Central Europe, the Balkans and Africa have a common feature of eating large quantities of fermented foods whose intake is associated with the activation of the Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) anti-oxidant transcription factor. There are many Nrf2-interacting nutrients (berberine, curcumin, epigallocatechin gallate, genistein, quercetin, resveratrol, sulforaphane) that all act similarly to reduce insulin resistance, endothelial damage, lung injury and cytokine storm. They also act on the same mechanisms (mTOR: Mammalian target of …

MAPK/ERK pathwayARIA groupAllergy[SDV]Life Sciences [q-bio]NF-KAPPA-BdebelostReviewPharmacologyResveratrolPROTECTSchemistry.chemical_compound0302 clinical medicineRESPIRATORY SYNDROME CORONAVIRUSENDOPLASMIC-RETICULUM STRESSMedicine and Health SciencesImmunology and AllergyMedicineOXIDATIVE STRESSCOVID-19; Foods; Insulin resistance; Nrf2; Nutrients; Obesity; TRPA12. Zero hunger0303 health sciencesRESPIRATORYINSULIN-RESISTANCEMuscle cell proliferationSULFORAPHANE3. Good health[SDV] Life Sciences [q-bio]Foods030220 oncology & carcinogenesisSIGNALING PATHWAYSignal transductionLife Sciences & BiomedicinePulmonary and Respiratory MedicineNRF2 ACTIVATORSMUSCLE-CELL PROLIFERATIONImmunology610 Medicine & healthLung injurySettore MED/10 - Malattie Dell'Apparato RespiratorioTRPA1Nrf2ACUTE LUNG INJURY03 medical and health sciencesInsulin resistanceCOVID-19 Foods Insulin resistance Nrf2 Nutrients Obesity TRPA1udc:616.9odpornost proti inzulinuSULFORAPHANE PROTECTSObesityTranscription factorPI3K/AKT/mTOR pathway030304 developmental biologyScience & Technologybusiness.industrySARS-CoV-2foodCOVID-19Insulin resistanceNutrientsmedicine.diseasechemistryhranilaSYNDROME CORONAVIRUSbusinesshranaGREEN TEA
researchProduct

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

2020

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). …

MDD0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisIMPACTBONE-MARROWFEATURESCHILDRENlong-term follow-uplcsh:RC254-282ArticleDISEASECLASSIFICATIONChildhood Anaplastic Large Cell Lymphoma03 medical and health sciences0302 clinical medicineInternal medicineADOLESCENTSmedicineVINBLASTINEProgression-free survivalYoung adultPathologicalAnaplastic large-cell lymphomachildhoodScience & Technologybusiness.industryHazard ratioCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCLALCL; MDD; childhood; long-term follow-up030104 developmental biologyOncology030220 oncology & carcinogenesisMinimal Disseminated DiseaseNON-HODGKIN-LYMPHOMAbusinessLife Sciences & BiomedicineCancers
researchProduct